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Our research, inspired by the pioneering works of Isaac Witz in the 1980s, established that 40% of human metastatic melanomas
express ectopically inhibitory Fc gamma receptors (FcγRIIB), while they are detected on less than 5% of primary cutaneous
melanoma and not on melanocytes. We demonstrated that these tumoral FcγRIIB act as decoy receptors that bind the Fc portion
of antimelanoma IgG, which may prevent Fc recognition by the eﬀector cells of the immune system and allow the metastatic
melanoma to escape the humoral/natural immune response. The FcγRIIB is able to inhibit the ADCC (antibody dependent cell
cytotoxicity)invitro.Interestingly,thepercentageofmelanomaexpressingtheFcγRIIBishigh(70%)inorgansliketheliver,which
is rich in patrolling NK (natural killer) cells that exercise their antitumoral activity by ADCC. We found that this tumoral FcγRIIB
is fully functional and that its inhibitory potential can be triggered depending on the speciﬁcity of the anti-tumor antibody with
which it interacts. Together these observations elucidate how metastatic melanomas interact with and potentially evade humoral
immunity and provide direction for the improvement of anti-melanoma monoclonal antibody therapy.
1.Introduction
Theanalysisofdiﬀerenttypesoftumorbiopsiesbyimmuno-
histochemistry for the expression of low aﬃnity receptors
for the Fc portion of IgG antibodies (FcγRII) showed that
melanomas are one of the rare non-hematopoietic tumors
that express FcγRIIB. This ectopic expression of FcγRIIB is
restricted to metastatic melanoma and is acquired during
the metastasis process. The tumor FcγRIIB found are fully
functional. They bind the Fc portion of IgG and retain the
ability to initiate an inhibition of cellular phosphorylation
cascades.
We will present the context of this expression of Fcγ
receptor. We will review the consequences of the FcγRIIB
expression by metastatic melanoma assayed in mouse
models. Finally, we will discuss its implications for human
therapeutic approaches.
2. FcγRinth eI m m uneS yst e m
2.1. Extra- and Intracellular Characteristics of FcγR. The
FcγR are glycoproteins that belong to the Immunoglobulin
Superfamily (IgSF) [1]. Their extracellular portions are
folded in two or three globular domains called “Ig-C2”
domainsofapproximately90aminoacidseach.Atypical“Ig-
C2” domain possesses an alternating succession of 8 β sheets
(A, A
 ,B ,C ,C
 ,E ,Fa n dG )a n d7α loops (AA
 ,A
 B, BC,
CC
 ,C
 E, EF and FG) (Figure 1). The β sheets form a bundle
stabilized by a disulﬁde bond between the two opposing
Ba n dFβ sheets. The BC, CC
 , EF and FG loops possess2 Dermatology Research and Practice
CD64 CD32 CD16
hFcγRI hFcγRIIA hFcγRIIB1 hFcγRIIB2 hFcγRIIC hFcγRIIIA hFcγRIIIB D2 D1
D3
D2 D1 D2 D1 D2 D1 D2 D1 D2 D1 D2 D1
γ2 γ2
α α
ITAM ITAM ITIM
ITIM
ITAM ITAM
αα
α
α
GPI
E
B
A
A 
G
FC C  
Ig-C2 domain
Fc
Fab
IgG
Fab
ITIM FcγRIIB1
D2 D1
Figure 1: The human Fc gamma Receptors. Structure of Human Fc gamma Receptors CD64, CD32, and CD16. The FcγRb e l o n g st ot h eI g
superfamily and possess Ig-C2 types of extracellular domains. The domain D2 of the FcγRIIB binds to the hinge region of the IgG.
Table 1: Aﬃnity of FcγRf o rt h eI g G .R e l a t i v ea ﬃnity of human and mouse Fc gamma receptors for the diﬀe r e n ti s o t y p e so fh u m a na n d
mouse Immunoglobulins G.
hFcγRIIB hFcγRIIA hFcγRIIIA hFcγRI
Ka <107 M <107 M1 - 2 ×107 M1 0 8-109 M
human IgG 3 > 1 = 4 ≫ 2 HR 3 > 1 ≫ 2,4 3 > 1 ≫ 2,4 3 = 1 > 4 ≫ 2
LR 3 > 1 = 2 ≫ 4
mouse IgG 2a = 2b > 1,3 HR 2a = 2b = 1 3 > 2a > 2b ≫ 12 a = 3   1,2b
LR 2a = 2b ≫ 1
mFcγRIIB mFcγRIII mFcγRIV mFcγRI
Ka <107 M <107 M3 ×107 M1 0 8 M
mouse IgG 1 = 2b > 2a ≫ 32 a = 2b = 1 ≫ 32 a = 2b ≫ 1,3 2a ≫ 1,2b,3
human IgG 3 > 1 > 2   41 = 3 > 2   41 , 3 3 > 1 > 4   2
asparagines, whose lateral chain NH function are candidates
for glycosylation. The FcγRI possess 3 Ig-C2 domains: the
N terminal D1, the D2 and the membrane proximal D3.
The FcγRII and FcγRIII possess two of these domains: the
N terminal D1 and the D2. The D1 is usually the more
glycosylateddomain[1–3].Glycosylationrepresentsbetween
30 and 45 percent of the molecular weight of the FcγR α
chain. The FcγR interact with the immunoglobulin G by
their domains D2, which recognize the hinge region of the
IgG.
The variations in size and structure of the IgG’s hinge
region, the nature and degree of glycosylation in the Fc
portion of the IgG, and the number of D domains and
diﬀerences in glycosylation of the FcγR are parameters that
modulate the binding aﬃnity of the diﬀerent IgG isotypes to
each one of the FcγR( Table 1).
The N-terminal extracellular domain of the FcγRi s
followed by a transmembrane domain (TM) of about 20
amino acids and by a C-terminal intracytoplasmic tail called
α chain, except in FcγRIIIB. This latter has an extracellularDermatology Research and Practice 3
domain covalently linked to a GPI (Glyco-Phosphatidyl
Inositol) moiety, which is anchored in the cytoplasmic
membrane [4].
The intracytoplasmic domains are more heterogeneous.
The FcγRI, FcγRIIA, FcγRIIB2 and FcγRIIIA are endocytic
receptors while the FcγRIIB1 possess a speciﬁc sequence
of membrane retention. The FcγRII are self-suﬃcient. The
intracytoplasmic domain of FcγRIIA and FcγRIIC contain
a signal-transducing unit called ITAM (Immunoreceptor
Tyrosine-based Activation Motif) [5, 6] whereas the FcγRIIB
contain an ITIM (Immunoreceptor Tyrosine-based Inhibi-
tion Motif) [7, 8]T h eF c γRI and FcγRIIIA do not possess a
signal-transducingunitbutformacomplexwithadimerofa
polypeptide chain containing an ITAM called “FcR γ chain”
(or FcεR γ chain, as it was ﬁrst described associated with
the FcR for IgE). The association of the α chains FcγRI and
FcγRIIIA with the FcR γ chains is required for cell surface
expression of these receptors [9]( Figure 1).
2.2. FcγR and Immune Functions. The Fcγ Receptors are of
high aﬃnity (FcγRI) when their extracytoplasmic domains
recognize monomeric IgG. They are of low aﬃnity (FcγRII,
FcγRIII) when they loosely recognize monomeric IgG but
bind avidly IgG complexed with their antigens (immune
complexes) [10–13]( Table 1). All FcγR belong to the
Ig superfamily and share sequence homologies for their
extracellular regions, but they diﬀer in their cytoplasmic
regions. They are further deﬁned by the way their aggrega-
tion initiates or inﬂuences the intracellular phosphorylation
cascades, which promote cellular activations versus cellular
inhibitions. The aggregation of activation receptors (FcγRI,
FcγRIIA, FcγRIIC and FcγRIIIA) initiates the phosphoryla-
tion of tyrosine of the ITAM by src-family protein tyrosine
kinase (PTK) that recruits kinases like Syk. This leads to the
phosphorylationbySykofdownstreamtargetsandtocellular
activations, which depend upon the cell type and include
cell degranulation, cytokine secretion, and phagocytosis
of immune complexes. In addition, the activating FcγR
on monocytes, macrophages, neutrophils, eosinophils, and
dendritic cells can mediate killing of IgG-sensitized target
cells by ADCC (Antibody Dependant Cell Cytotoxicity).
Alternative splicing produces two isoforms of the human
inhibitory receptors FcγRIIB. The FcγRIIB1 possess a 19
amino acid membrane retention sequence absent from the
FcγRIIB2. The FcγRIIB2 are endocytic receptors expressed
by monocytes, macrophages and dendritic cells and are
involved in regulation of antigen processing and presenta-
tion. The FcγRIIB1 are non-endocytic receptors expressed
in B cells and mastocytes. The inhibition receptor FcγRIIB1
coaggregation with an activation receptor containing a
pITAM, like a triggered BCR (B Cell Receptor), initiates
an inhibition message. The pITAM recruits the src-family
protein tyrosine kinase Lyn, which phosphorylates the
tyrosine of the FcγRIIB1 ITIM. Then the pITIM recruits
the hematopoietic speciﬁc inositol phosphatases SHIP, (the
ubiquitous SHP1 or SHP2 tyrosine phosphatases can poten-
tially be recruited), which shut down the phosphorylation
cascade of activation [14]. FcγRIIB homoaggregation alone
may or may not induce the ITIM tyrosine phosphorylation.
InhumanBcells,itinducesthephosphorylationoftheITIM,
which leads to cellular inactivation of human peripheral IgM
(+) B cells [15]. In mice, it does not phosphorylate the ITIM
but induces a Btk dependent apoptosis on class-switched IgG
(+) B cells and plasma cells [16–18].
2.3. The FcγR-Dependent Anti-Tumor Defenses. In some
patients suﬀering from cancer lesions, serum IgG antibod-
ies are present that recognize cancer cells, form immune
complexes and consequently activate FcγR. A sustained
serological anti-tumor response occurs in patients with
melanoma,whichincludesIgGantibodiesagainstcellsurface
tumor antigens such as the cancer/testis antigens (NY-ESO-
1, MAGE, SSX) and tyrosinase [19–21]. An indication that
the serological response is beneﬁcial comes from vaccination
studies, which have demonstrated a signiﬁcant associa-
tion between the development of an anti-tumor antibody
response and survival of melanoma patients [22–24]. The
eﬃcacy of therapeutic IgG antibodies against hematopoietic
and epithelial tumors argues for an important role of IgG
antibodies in anti-tumor defenses [25, 26].
Immune complexes can be involved in the aﬀerent part
of the anti-tumor immune response and increase antigen
presentation [27, 28]. Moreover, anti-tumor IgG can partici-
pate in tumor destruction by activating the cytotoxic activity
of FcγR positive cells. Indeed, in vitro studies have demon-
strated Fc-dependant mAb mediated ADCC of cell lines
derived from solid and lymphatic tumors by FcγR expressing
monocytes, macrophages, eosinophils, neutrophils, and NK
cells [29, 30]. In early studies, the capability of mAb to
elicit tumor regression was found to depend on FcγR-
expressing eﬀector cells and the rate of tumor rejection was
correlated with the density of FcγR-expressing eﬀector cell
inﬁltration at the tumor site after antibody therapy [31]. The
Ab isotype, which induced the strongest depletion of tumor
cells, correlates with the most active subclass in ADCC [30–
32]. In a clinical study comparing isotype switch variants of
alemtuzumab speciﬁc for CD52, the strongest depletion of
malignant cells was obtained with the antibody isotype that
most eﬀectively induced ADCC in vitro [29]. Studies in Fc
receptor deﬁcient nude mice indicate that anti-tumor eﬀects
of mAbs, such as anti-CD20 mAb (rituximab) and anti-
HER2 (trastuzumab), need the presence of the FcR γ chain
to be eﬃcient.Macrophagesinthelunghavebeenimplicated
[33]. In the B16 metastatic mouse melanoma model FcγRI
[34]a n dF c γRIV(CD16-2) [35], the equivalent of the human
FcγRIIIA, were found to play a major role in the therapeutic
eﬀect of the TA99 mAb (a mAb anti-tyrosinase associated
protein gp75) [36, 37].
The FcγR-dependent therapeutic eﬀects of IgG anti-
tumor antibodies are counterbalanced by the inhibitory
FcγRIIB. Indeed, it was shown that the coexpression of
host FcγRIIB and activation FcγRo ne ﬀector cells when
engaged together down modulates the anti-tumor eﬃciency
of rituximab and trastuzumab [38].
However, early complement component such as degra-
dation products of C3 might be involved as illustrated by the4 Dermatology Research and Practice
lower susceptibility of CD11c/CD18 deﬁcient mice to TA99-
antibody therapy against mouse metastatic melanoma B16
[39].
3. Expression of Tumor FcγRIIB
3.1. FcγRII and Tumor: First Observations. Since the 1970’s,
it has been suspected that FcγR could be expressed by non-
hematopoietic cell types and tumors.
Neural crest derived cells have been reported to express
the FcγR. Examples are the Langehrans cells [40, 41], which
express the FcγRIIB2 [42], the Schwann cells, which express
the FcγRIII [43] and the Purkinje cells, which express the
FcγRIIB [44]. Endothelial and trophoblastic cells of the
placentaexpressFcRn,aswellasFcγRIIandFcγRIII[45,46].
In Graves’ Disease, the thyroid epithelial cells (thyrocytes)
express the FcγRIIB2 [47].
Milgrom et al. ﬁrst proposed a tumoral expression of
FcγR. They used a cryostat hemadsorption technique to
demonstrate that tissue sections of diﬀerent mouse sarcomas
adsorbed antibody-coated sheep erythrocytes (SRBC) [48].
In humans, Tonder and Thunold reported that various
non-hematopoietic malignant tumors adsorbed SRBC in
a manner dependent on the Fc portion of the antibody
[49]. At the same time, Isaac Witz showed the presence
of IgG within non-lymphoid tumor tissue and observed
that these IgG did not exhibit any antibody activity against
tumor antigens, suggesting that they bound to tumor cells
via their Fc region [50]. This hypothesis was supported by
further experiments where primary cultures of tumors and
SRBC formed rosettes [51, 52]. In addition, it was observed
that tumor cells injected in mice immunized with non-
tumoral antigens were able to bind antibody via their Fc
region [53]. However, the ectopic expression of FcγRb y
non-hematopoietic tumors cells was controversial because
the presence of inﬂammatory cells, which can express
FcγR, was demonstrated early at the tumor site [54]a n d
because FcγR expression was lost during short-term tumor
cell in vitro culture [55]. Nevertheless, it was shown that
the experimental tumors regained expression after a single
passage in vivo [56] and that some tumor cell lines express
FcγR[ 57]. Moreover Gorini et al. described the presence
of FcγR on the cell surface of two human neuroblastoma
cell lines using immunohistochemistry and ﬂow cytometry
analysis [58]. It is worth noting neuroblastoma are tumors
of young children that can arise from any part of the neural
crest.
Using experimental models, it was previously suggested
that host factors are involved in the induction of FcγR
expression by tumor cells. Ran et al. observed that anaplastic
carcinoma originally induced by polyomavirus (PyV) and
BALB/c 3T3 cells transformed in vitro with PyV acquired
FcγR expression only after being passaged in syngeneic
animals as solid tumors [56].
3.2. Melanoma Express the FcγRIIb: Immunohistochemical
Analysis. The analysis of the expression of FcγRb yn o n -
hematopoietic human tumor cells has been realized by
immunohistochemistryonasmallnumberoffrozensections
of biopsies [59]. Later on, the technique was adapted for 259
primary tumors and 187 metastatic lesions from 12 diﬀerent
cancer types on paraﬃn-embedded sections with an anti-
FcγRIIB rabbit antibody speciﬁc for the intracytoplasmic
domainofthereceptor[60].Themorphologyofthecellsand
double staining with a tumor marker allowed identiﬁcation
of the expressing cells as cancer cells and not inﬁltrating
cells. The analyses show that 24% (49/203 biopsies) of
melanoma lesions were positive for the expression of FcγRII.
Metastatic melanoma appeared as the tumor with the
highest percentage of FcγRIIB expression at 34% (45/121
biopsies),farmorethanprimarymelanomaat5%(4/82)and
other non-hematopoietic carcinoma (ovary, brain and colon
carcinomacounted,respectively,at14%,5%and4%positive
biopsies). By comparing the origin of the lesions, it appears
that liver and lymph node metastases with, respectively,
69% and 44% of positive tumors express higher levels of
FcγRIIB while lung and skin metastasis express lower levels
of20%and10%,respectively.Thisglobalpatternleadstothe
proposition that the expression of FcγRIIB correlates with
the metastatic progression of the tumor. This hypothesis is
reinforced by the ﬁnding that patients, for which there are
time point biopsy histories, show an absence of FcγRIIB
expressioninprimarylesionsandanexpressionatmetastatic
stages only in the liver and lymph nodes, and not in the skin
[60].
3.3. Gain and Stability of FcγRIIB Expression by Melanoma
Cells. It is still unknown how non-hematopoietic tumors
acquire the expression of FcγRII. Viral induction has been
proposed by Witz for anaplastic carcinoma induced by
polyomavirus (PyV). In mouse 3T3 cells transformed by
PyV, expression was acquired in vivo and lost in vitro [56].
The loss of FcγRIIB expression following in vitro culture
was reported for other non-hematopoietic expressers like
Schwann cells or Purkinje cells [61].
When cells derived from frozen biopsies were selectively
enriched for the FcγRIIB1 expression and positive clones
were established as cell lines in vitro, the phenotype analysis
conﬁrmed the melanoma identity of most of these cell
lines by the expression of melanoma marker (GD2, Mel/14)
and the absence of hematopoietic cells marker (CD45,
CD14, CD1a, CD4, CD15, CD20). The analysis of these
cell lines karyotypes, which never showed tetraploidy but
presented very speciﬁc melanoma chromosomal abnor-
malities, reinforced the identiﬁcation and excluded fusion
with hematopoietic cells. Interestingly, the expression of
FcγRIIB was stable in culture in vitro for several years. The
biochemical analysis established the expression of only the
FcγRIIB1 isoform [59].
Several hypotheses can be proposed to explain the
acquisition of FcγRIIB1 expression at the metastasis stage.
One possibility might be that the presence of IgG-containing
immune complexes within tumors may upregulate FcγRII
expression on tumor cells, a phenomenon previously
observed in vitro in cell lines of hematopoietic origin [62].
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may induce the expression of FcγRIIB1 on tumor cells. One
example is IL-4, a cytokine known to upregulate FcγRIIB
on human macrophages [63]. Interestingly, melanocytes are
of neural crest origins and melanoma express de novo some
neural crest cell speciﬁc proteins, like bone morphogenic
proteins BMP-4 and BMP-7, expression of which is depen-
dent on the master transcription factor Ets-1. BMP proteins
are expressed in metastatic melanoma and are prometastatic
[64]. It could be that FcγRIIB are derepressed or actively
transcribed by a similar dediﬀerentiation process.
4. Physiological Consequenceof Melanoma
FcγRIIB1 Expression
4.1. Eﬀect of PyV-Induced FcγRIIB on Carcinoma Metastasic
Behavior. Witz’s experiments suggested that the induction
of FcγRIIB in vivo in PyV induced carcinoma would be
the result of a positive “selection” by the gain of metastatic
or proliferative capabilities, a process called immunoediting
of tumors [65]. Zusman et al. demonstrated that in 3T3
cells transfected to express the mouse FcγRIIB1, the mouse
FcγRIIB2 or a deletant for the intracytoplasmic domain
of the mouse FcγRIIB, only the full FcγRIIB conferred
enhanced tumorigenicity (the IIB1 more than the IIB2)
[66] and that the intracellular domain of the receptor
was involved in the phenotype [67]. The hypothesis was
that the Complement Dependant Cytotoxicity (CDC) and
the ADCC defense mechanism would be impaired by the
tumor FcγRIIB1. It was not clear to which extent the
intracytoplasmicdomainofthereceptorwasneeded.Itcould
be necessary for the receptor retention at the cell membrane,
for the signaling through the ITIM and the triggering of
phosphatase SHP or for both of these properties of the IC
domain.
4.2.XenograftofFcγRIIB1+ MetastaticMelanomainImmuno-
compromised Mice. To evaluate the eﬀects of tumor
FcγRIIB1 expression on melanoma growth and metastasis,
the tumors derived from biopsies were grafted to immuno-
compromised nude and SCID mice [59]. Nude mice are
impaired for the T cell response but able to mount a B
cell xenogenic response characterized by the secretion of
antimelanoma antibodies, principally of the mouse IgM
and IgG3 isotypes. These mouse immunoglobulins have no
aﬃnityformouseFcγRbutmIgG3bindshumanFcγR.SCID
mice are unable to engage in BCR and TCR gene recombi-
nation; they show no mature T or B cells, have no serum
Ig titer and reject neither allo- nor xenografts. Spontaneous
expressers of human tumor FcγR I I B 1a sw e l la st r a n s f e c t a n t
melanoma cell lines were inhibited in their subcutaneous
growth in nude mice. This inhibition was dependent of
the intracytoplasmic domain of the human FcγRIIB1 as
transfected melanoma expressing human FcγRIIB1 lacking
the intracytoplasmic domain were not aﬀected in their
growth. In SCID mice as well as in vitro, the proliferation
of the tumors were unaﬀected by the FcγRII expression.
Antimelanoma mIgG3 bind to the tumor antigen by its Fab
region and to the human tumor FcγRIIB1 by its Fc region.
This crosslink triggered the phosphorylation of the ITIM
domain of the receptor, whose pTyrosine interacts with the
SH2domainofSHP-2(noco-precipitationofSHP-1orSHIP
wasdetectedinHT144melanomacellline).Thephosphatase
activity inhibits cell proliferation and tumor development.
This system does not trigger the immune system of the
host, as mouse FcγRh a v en oa ﬃnity for mouse IgG3
(Table 1), and ADCC is bypassed. One intriguing question
is relative to the role of SHP-2. The eﬀects of upregulation
of SHP-2 are controversial; some studies attribute to SHP-
2 overexpression an increase in metastatic potential [68, 69],
othersadecrease[70].Inparticular,inarecentstudyonlung
adenocarcinoma, SHP-2 upregulation has been associated
with an inhibition of migration (by phosphorylation of
Hef1/Cas-L), which suggests that a downregulation of SHP-
2 expression could be associated with a gain of migratory
potential [70]. One can ask if highly metastatic melanoma,
which express FcγRIIB1, would not be low SHP-2 expressers.
4.3. Allogenic and Syngenic Graft of Mouse FcγRIIB1+
Melanoma in Immunocompetant Mice. To evaluate the
immunologic host-tumor relationship a murine model was
used [60]. The C57BL/6 (H2b) melanoma cell line B16 is
indeed slightly immunogenic and as a pigmented cell line,
extremely sensible to the eﬀect of anti-tyrosinase antibodies
[71].Withthismodel,ahallmarkofsuccessinimmunization
protocols or passive transfer of anti-tyrosinase antibodies is
post-treatment vitiligo [72]. The B16 melanoma transfected
to express the mouse FcγRIIB1 receptors either intact
or ITIM invalidated by Y→A mutation were grafted in
syngeneic host C57BL/6 mice [60]. The tumor uptake and
the growth in the syngeneic host were indiﬀerent to the
presenceofmFcγRIIB1.IntheallogeneichostBALB/c(H2d)
(albino mice that do not express tyrosinase [73]), the B16
tumorwasstronglyrejectedandpuriﬁedanti-B16antibodies
from BALB/c mice were suﬃcient to transfer the rejection
o fB 1 6i nS C I Dm i c ei na nA D C Cd e p e n d e n tw a y[ 60]. The
more striking observation was the ability of B16 (FcγRIIB1)
or B16 (FcγRIIB1 ITIM
Y→A) grafted subcutaneously in
BALB/c mice to counteract the allogenic rejection and
grow (Joel Cohen-Solal, unpublished data). These results
propose that FcγRIIB1 possess the ability to protect the
melanoma from the humoral antimelanoma immunity and
from the allogenic rejection. This later consideration could
highlight the mechanism of allogenic tolerization of the
fetus proposed by Clark Anderson. The yolk sac membranes,
which are of fetal origin, express FcRn and FcγRIIB as well as
paternal/maternal MHC molecules and are protected from
maternal allogenic antibody mediated cell cytotoxicity.
5. Mechanismof Action of Melanoma FcγRIlB
5.1. Inhibition of ADCC In Vivo and In Vitro. In C57BL/6
mice, the growth of the melanoma B16 is inhibited by
treatment of the mice with the mouse IgG2a monoclonal
antibody TA99 anti-Tyrosinase Associated Protein TYRP-
1/gp75 [72]. In this model, the antibody action is entirely
dependent of the FcR γ chain of the eﬀector cells of the host.6 Dermatology Research and Practice
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Figure 2: Tumor FcγRIIB1 expression protects metastatic melanoma from ADCC. Metastatic melanomas that express the FcγRIIB1 are
resistant in vitro and in vivo in immunocompetent mice to the ADCC mediated by FcR γ chain dependent eﬀector cells (NK cells,
neutrophiles monocytes, or macrophages). The tumor FcγRIIB1 are decoy receptors. The Fc portions of anti-tumor antibodies are captured
by the tumor FcγRIIB1 and cannot interact with the Fcγ of the immune eﬀector cells.
T h e s er e c e p t o r sa r et h eF c γRI, FcγRIII and FcγRIV (CD16-
2) and the cells that express them are NK cells, macrophages,
monocytes and neutrophils [39, 72, 74–76]. The expression
of the tumor FcγRIIB and FcγRIIB invalidated ITIM
Y→A
antagonize the therapeutic eﬀect of TA99. The ADCC
inhibition is also observed in vitro with human melanomas
expressing FcγRIIB1 full or deleted of its intracytoplasmic
domain [60]. This result suggests that the expression of
FcγRIIB1 has the ability to inhibit the ADCC mechanism
independently of the ITIM function. The simplest view is a
mechanismofdecoyreceptor:theanti-tumorantibodybinds
the tumor by its Fab portion while its Fc portion is caught by
the tumor FcγRIIB1 and cannot be recognized by the FcγR
of the eﬀector cell (Figure 2).
5.2. Inhibition of Growth In Vivo and In Vitro. The nevis
and primary melanoma express the gangliosides GD3 and
GM3. Upon metastasis, they acquire the expression of
the enzyme N-acetylgalactosaminyl transferase that converts
GD3 into GD2 [77]. Anti-GD2 monoclonal antibodies are
used in radiotherapy, coupled to radioelements like 131I
or 188Re. There exist two well-documented mouse anti-
GD2 antibodies called 7A4 (mouse IgG3) and 3F8 (mouse
IgG3) [78, 79]. Mouse IgG3 bind to human FcγRa n d
have a cell cytotoxicity, which depends of activation FcγR
and complement receptor of the human host eﬀector cells.
They have no eﬀect in vitro on the melanoma proliferation.
Surprisingly, the melanomas that express the FcγRIIB1 are
inhibitedintheirinvitroproliferationaswellasinvivowhen
grafted in SCID mice following treatment with 7A4 [59].
The inhibition is dependent on the intracellular domain of
the receptor and the ITIM module is phosphorylated and
recruits the tyrosine phosphatase SHP-2 [80]. The simplest
explanation of the phosphorylation is the recruitment of a
scr-kinaselinkedtotheantigenthatisrecognizedbytheanti-
tumor antibody, which crosslinks it to the FcγRIIB1 by its Fc
portion.Thenthescr-kinasephosphorylatestheITIM,which
in the case of the availability of a phosphatase to bind the
pITIM, transduces a dephosphorylation wave that inhibits
cell proliferation (Figure 3).
5.3. The Nature of the Tumor Antigen Matters. These results
propose that the FcγRIIB1 retains its functionality and
that its expression could be selected as well as counter-
selected depending on the type of antigen recognized by
the anti-tumor antibody. Gangliosides like GD3 and GD2
are localized in cholesterol rich microdomains where src-
kinases are present. If they attract the FcγRIIB1 in the
microdomains, they may promote the phosphorylation of
their ITIM and give a selective advantage to the melanoma
that do not express FcγRIIB1 [59]. Antigens like TYRP-gp75,
and Mel14-gp90MEL, which are transmembrane proteins
not associated with kinase activities, will not promote the
ITIM phosphorylation but rather promote the conﬁnement
of the antimelanoma Ab and give a selective advantage to the
melanoma that express the FcγRIIB1 [60].
6. Anti-Melanoma Monoclonal Antibodies and
Patient Care
6.1. Clinical Trials. Several clinical trials are reported in the
USA that use antimelanoma mAb; the main targets are GD2,Dermatology Research and Practice 7
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Figure 3: Tumor FcγRIIB1 expression inhibits metastatic melanoma growth. Metastatic melanomas that express the FcγRIIB1 receptor are
sensibletotheactionofanti-GD2mAb.InvitroaswellasinvivoinimmunocompromisedmicethetumorFcγRIIB1thatareaggregatedwith
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GD3, Mel14 and melanin (http://clinicaltrials.gov/). One
protocol is an immunization with an anti-idiotype antibody
4B5 (Ab2), which forms an “internal image” of the antigen
GD2. The goal is to mount an anti-GD2 response. The
other therapies are based on mAb coupled to radiolabeled
elements (131Ia n d188Re). With the exception of the anti-
idiotype vaccination, the other therapies do not require the
immune eﬀector cells of the host, moreover they try to avoid
it by the use of F(ab)
 2 fragment of the antibodies. These
therapies are based on the local irradiation of the cells that
are bound to the antimelanoma antibodies. By avoiding the
binding to activator FcγR these antibodies do not deplete the
host immune eﬀector cells. For these protocols, the tumoral
expression of FcγRIIB is without eﬀect. For the anti-idiotype
vaccination this could partially explain the poor response
of patients. In protocols of active vaccination in contrast to
inductionofanti-tumorIgM,theincreaseofcirculatinganti-
melanoma IgG was associated with a poor prognosis [81–
83].
6.2. Optimizing the Fc of mAb. The recent studies of the
structureofIgGandtheirinteractionswiththediﬀerentacti-
vator FcγR have allowed the design of optimized antibody
Fc fragments, which is already a reality with two products
on the market (eculizumab and catumaxomab) and about
ten candidates in clinical trial. The main modiﬁcations target
the glycosylation and the binding sites for C1q and FcγR.
The eﬀects of the modiﬁcation are evaluated on ADCC,
Antibody Dependent Cell Phagocytosis (ADCP) and CDC
[84–86]. The treatment of melanoma will beneﬁt from this
amazing work realized over ten years, which allows enhanced
binding to FcγRIIA and FcγRIIIA and lower binding to the
FcγRIIB and which is exactly what is needed to counteract
the tumor FcγRIIB1 expression. An increase of 100-fold in
ADCCeﬃciencyiscommonlyreportedwiththeseantibodies
[84, 87]. This high level of improvement and the safety of the
product will certainly give a second chance to the neglected
mAb therapy based on the immune eﬀector function in
melanoma treatment.
6.3. Modulation of the Immune System with an Anti-Human
FcγRIIB Antibody. The immunization of a mouse transgenic
for the human FcγRIIA with the extra-cellular moiety of
the human FcγRIIB allowed the development of a set of
mouse anti-human FcγRIIB monoclonal antibodies. One of
them, 2B6, was selected for its ability to interact solely with
the FcγRIIB without crossreacting with either the FcγRIIA
or the FcγRIIC and to block the Fc-FcR interaction [88].
2B6 was modiﬁed to reduce its immunogenicity in human
by chimerism (xi-mAb) and humanization (zu-mAb). It
successfullydepletes B cellsexpressing the FcγRIIBby ADCC
[89]. It can potentially modulate the immune system. It has
been postulated that T cell mediated anti-melanoma immu-
nity could be enhanced by B cell depletion as melanoma
development is impaired in B cell deﬁcient μMT mice [90].
The use of multi-monoclonal antibody therapy could be
envisionedwithanti-melanomaantibodiesandanti-FcγRIIB
antibodies targeting both melanoma and B cells. However,
recent work based on the B16 melanoma model showed the
preponderant role of the B cell compartment in the anti-B16
immune response [91]. To address this issue, further studies
are needed that will speciﬁcally evaluate the extent to which
the use of 2B6 (or another anti FcγRIIB mAb) associated to
a monoclonal anti-melanoma therapy could be beneﬁcial.
7. Conclusion
The work that we accomplished over the last ten years
demonstrated and quantiﬁed the ectopic expression of FcγR
by melanoma. We established that FcγR are selected during
the course of the metastasis and that their expression
culminates at the later stages in the liver or the lymph nodes.
We observed that the expression of FcγRi sr e s t r i c t e dt o
the IIB1 form of receptor, which possess an inhibitor motif
ITIM and a membrane retention intracytoplasmic sequence.8 Dermatology Research and Practice
The expression of the receptor was heterogeneous inside
tumor lesions and was dependent on the site of metastasis
and most probably to the relation tumor-host. FcγRIIB1
seem immuno-edited by the presence of activity, which
they antagonize in vitro and in vivo in mouse models. In
contrast, they are counter-selected in absence of the pressure
ofeﬀectorcells,asobservedinvitroandinvivoinnudemice.
On one hand, FcγRIIB1 are not detected in melanocytes.
They are rarely seen in primary tumors where the Fc
dependent eﬀector functions are described as impaired.
Eﬀectively, in primary melanoma lesion, suppressor T cells
and tolerizing dendritic cells (DC) deactivate the immune
response.TGFβ1/2andIL-10arethemosteﬀectivecytokines
responsible for the lack of DC maturation [92]. TGFβ have
the ability to downregulate the FcR γ chain expression,
which reduces the membrane expression of activator FcγR
in myeloid eﬀector cells [93] and IL-10 upregulates inhibitor
FcγRIIB1/2 [94]. Additionally, TGFβ inhibit IFNγ secretion
and ADCC in human NK cells [95]. On the other hand,
FcγRIIB1 is highly expressed in metastatic tumors in the
spleen or in the lymph nodes [60]. These melanomas have
gained a high metastatic power and reside in the liver,
which is an environment rich in NK and NKT cells. Tumor
FcγRIIB1expression appearsasa decoy mechanism, whichis
able to counteract the ADCC mediated humoral immunity.
The suppressive eﬀe c ti sp o w e r f u le n o u g ht oa l l o wt h e
allogenic uptake and growth of the C57BL/6 derived B16
tumor in BALB/c mice, which suggest that it should be
preponderant in the weak eﬃciency of the passive transfer
of anti-tumor antibodies and of antibody-based vaccination.
The optimization of Fc domain of therapeutic antibodies
is now possible and allows for a higher ADCC, ADCP and
CDC potential. In the case of anti-FcγRIIB1+ metastatic
melanoma therapy, the optimization will be reached by
lowering the Fc binding to the FcγRIIB binding and by
increasing the Fc binding to FcγRIIIA and FcγRI. The reality
of these eﬃciency improvements and the innocuousness
of humanized antibodies ensure that mAb anti-melanoma
approaches will be revisited in a near future.
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